Journal: Kidney and Blood Pressure Research
Submission Deadline: February 28, 2025
Clinical Nephrology is living a paradigm shift, from a focus on solution for kidney failure towards preventing and slowing its progression. This has been possible thanks to the development of new molecules with proved efficacy on kidney protection and, for the first time, even on the reduction of cardiovascular risk. Several molecules are already on the market, others are in the pipeline. Major innovations have occurred for the management of kidney failure, however new options are available also for rare kidney diseases. Since these new drugs have the potential to transform clinical practice and provide new hope to improve the lives of patients with kidney diseases, there is a major need to communicate the latest research in this growing area to allow widespread clinical use and achieve better therapeutic effects.
In recognition of the robust novel therapeutic strategies for the management of kidney disease, Kidney and Blood Pressure Research is launching an article collection on “Novel Drugs in the Nephrology Arena”. Authors are welcome to submit research articles and reviews describing advances in the treatment of kidney disease with a focus on new drugs for the management of CKD and rare kidney diseases. By addressing these topics, authors can contribute valuable insights on the latest therapeutic approaches for the management of kidney diseases for clinicians to use them more appropriately and achieve better-informed solutions in their clinical practice.
Please select the option “Call for Papers: Novel Drugs in the Nephrology Arena” when submitting your manuscript and mention this Call for Papers in your cover letter.
Karger has established agreements with consortia and institutions that include full or partial coverage of Article Processing Charges (APC). Corresponding authors can publish Open Access articles at no or reduced cost if they are associated with or employed by one of these universities/institutions.
Check out the Author Guidelines.